The University of Pennsylvania spinout's first applications of the platform are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. The technology leverages advances in macrophage biology, CAR engineering and adoptive cellular therapy for the treatment of human disease.

In September 2022, Carisma announced a plan to merge with US biotech Sesen Bio.